Phinomics, a Stanford spin-off from Andrew Fire's Nobel Prize-winning laboratory (2006), was established by a renowned team specializing in Genomics and Biophysics. Phinomics’ innovative and patented technologies generate datasets that transcend the conventional realm of whole-genome sequencing (WGS), capturing an elusive component of the human genome: extrachromosomal circular DNAs (eccDNAs). These circular genetic elements are swiftly emerging as pivotal players in over half of all cancers and in drug resistance. The presence of oncogenes on circular molecules, as opposed to the linear genome, accelerates tumor evolution and contributes to drug resistance through elevated gene expression, copy-number amplification, epigenetic modifications, novel sequences/gene-fusions, and other mechanismsIn addition, there are promising applications of these molecular species in additional biological settings such as the microbiome, immune response, and a broad class of gene-therapy vectors.